Industry Strength Score
68/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
NUVATION BIO INC (NUVB) Stock Price & Overview
NYSE:NUVB • US67080N1019
Current stock price
4.49 USD
+0.04 (+0.9%)
At close:
4.51 USD
+0.02 (+0.45%)
After Hours:
The current stock price of NUVB is 4.49 USD. Today NUVB is up by 0.9%. In the past month the price increased by 1.81%. In the past year, price increased by 82.52%.
NUVB Key Statistics
52-Week Range1.57 - 9.75
Current NUVB stock price positioned within its 52-week range.
1-Month Range4.215 - 5.29
Current NUVB stock price positioned within its 1-month range.
- Market Cap
- 1.561B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.60
- Dividend Yield
- N/A
NUVB Stock Performance
Today
+0.9%
1 Week
-8.18%
1 Month
+1.81%
3 Months
-14.31%
Longer-term
6 Months -13.98%
1 Year +82.52%
2 Years +44.84%
3 Years +177.16%
5 Years -68.42%
10 Years N/A
NUVB Stock Chart
NUVB Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to NUVB. When comparing the yearly performance of all stocks, NUVB is one of the better performing stocks in the market, outperforming 85.29% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
NUVB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NUVB. Both the profitability and financial health of NUVB have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
NUVB Earnings
On March 2, 2026 NUVB reported an EPS of -0.11 and a revenue of 41.87M. The company missed EPS expectations (-20.68% surprise) and beat revenue expectations (9.96% surprise).
Next Earnings DateMay 4, 2026
Last Earnings DateMar 2, 2026
PeriodQ4 / 2025
EPS Reported-$0.11
Revenue Reported41.865M
EPS Surprise -20.68%
Revenue Surprise 9.96%
NUVB Forecast & Estimates
17 analysts have analysed NUVB and the average price target is 11.83 USD. This implies a price increase of 163.52% is expected in the next year compared to the current price of 4.49.
For the next year, analysts expect an EPS growth of 18.49% and a revenue growth 218.62% for NUVB
Analysts
Analysts82.35
Price Target11.83 (163.47%)
EPS Next Y18.49%
Revenue Next Year218.62%
NUVB Index Membership
NUVB is currently included in the following stock indexes tracked on ChartMill.
NUVB Financial Highlights
Over the last trailing twelve months NUVB reported a non-GAAP Earnings per Share(EPS) of -0.6. The EPS decreased by -15.38% compared to the year before.
Income Statements
Revenue(TTM)62.90M
Net Income(TTM)-204.63M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.4% | ||
| ROE | -66.93% | ||
| Debt/Equity | 0.65 |
Chartmill High Growth Momentum
EPS Q2Q%26.67%
Sales Q2Q%633.06%
EPS 1Y (TTM)-15.38%
Revenue 1Y (TTM)698.96%
NUVB Ownership
Ownership
Inst Owners62.19%
Shares347.69M
Float281.81M
Ins Owners17.69%
Short Float %17.85%
Short Ratio11.92
NUVB Industry Overview
NUVB operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
47%
Outperformed 47% of sub-industries
3 Month Rank
55%
Outperformed 55% of sub-industries
6 Month Rank
42%
Outperformed 42% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 5.2%
- New Lows
- 3%
- Average ROE
- 96.3%
- Average Profit Margin
- 29.8%
- Average Operating Margin
- 41.4%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.8
- Average Debt/Equity
- 1.3
NUVB Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.63 | 910.173B | ||
| JNJ | JOHNSON & JOHNSON | 17.91 | 547.212B | ||
| MRK | MERCK & CO. INC. | 11.43 | 277.022B | ||
| PFE | PFIZER INC | 8.81 | 149.775B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 118.87B | ||
| ZTS | ZOETIS INC | 16.14 | 48.007B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.57 | 28.541B | ||
| VTRS | VIATRIS INC | 6.03 | 17.513B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.39 | 11.241B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.564B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.809B | ||
| CORT | CORCEPT THERAPEUTICS INC | 35.54 | 5.47B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NUVB
Company Profile
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The firm's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Company Info
IPO: 2020-07-01
NUVATION BIO INC
1500 Broadway, Suite 1401
New York City NEW YORK 94103 US
CEO: David Hung
Employees: 298
Phone: 13322086102
NUVATION BIO INC / NUVB FAQ
What does NUVATION BIO INC do?
Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in New York City, New York and currently employs 298 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. Its programs include taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). The firm's Taletrectinib is an oral, potent, central nervous system-active, selective, ROS1 inhibitor specifically designed for the treatment of patients with ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). Safusidenib is a novel, oral, potent, brain penetrant, targeted inhibitor of mutant isocitrate dehydrogenase 1(mIDH1). NUV-1511, a clinical-stage drug-drug conjugate (DDC), fuses a targeting agent to a widely used chemotherapy agent. Its NUV-868 is a BD2-selective, oral, small molecule bromodomain and extra-terminal (BET) inhibitor that inhibits BRD4.
Can you provide the latest stock price for NUVATION BIO INC?
The current stock price of NUVB is 4.49 USD. The price increased by 0.9% in the last trading session.
What is the dividend status of NUVATION BIO INC?
NUVB does not pay a dividend.
What is the ChartMill technical and fundamental rating of NUVB stock?
NUVB has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Would investing in NUVATION BIO INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NUVB.
What is NUVATION BIO INC worth?
NUVATION BIO INC (NUVB) has a market capitalization of 1.56B USD. This makes NUVB a Small Cap stock.
What is the ownership structure of NUVATION BIO INC (NUVB)?
You can find the ownership structure of NUVATION BIO INC (NUVB) on the Ownership tab.